Palbociclib is approved for HR+/HER2- advanced breast cancer and is used with letrozole or other aromatase inhibitors as initial therapy, or with fulvestrant after prior endocrine treatment. It is approved for both women and men and is continued until the cancer progresses or side effects become unacceptable.

Palbociclib is a CDK4/6 inhibitor that slows cancer growth by blocking the overactive cell cycle in HR+ breast cancer. It prevents CDK4/6 from activating the Rb protein, stopping cells from moving from the G1 to the S phase, which reduces cancer cell division and helps control tumor growth.

Palbociclib is taken orally once daily with food, following a 21-days-on/7-days-off cycle. Swallow the tablet or capsule whole and take it at the same time each day.

Palbociclib commonly causes low blood cell counts such as neutropenia, leukopenia, anemia, and thrombocytopenia, which can increase infection risk. Other frequent side effects include fatigue, nausea, diarrhea, mouth sores, reduced appetite, vomiting, and hair thinning. Less common but serious effects include febrile neutropenia, blood clots, and liver issues. Regular blood tests are needed to monitor safety during treatment.

Palbociclib should not be used in patients with known allergies to the drug. Caution is needed in those with bone marrow suppression, liver problems, or a history of infections, as it can cause significant myelosuppression. Regular blood count monitoring is required. Strong CYP3A inhibitors or inducers should be avoided. It is not recommended during pregnancy or breastfeeding, and effective contraception is advised during treatment and afterward.

Palbociclib is an important treatment for HR+/HER2- advanced breast cancer, slowing cancer growth by targeting CDK4/6 and working well with endocrine therapy. Approved for both women and men, it has improved outcomes and expanded treatment options. Though side effects like neutropenia and fatigue can occur, proper monitoring makes it a well-tolerated and effective therapy.

Palbociclib inhibits CDK4/6 activity, halting cell cycle progression at the G1 phase. When combined with endocrine therapy (e.g., letrozole or fulvestrant), it targets both hormonal signaling and cell cycle control, providing a synergistic effect that significantly delays disease progression.

This schedule allows for recovery of the bone marrow, minimizing the risk of severe neutropenia. The 7-day break helps reduce cumulative hematologic toxicity while maintaining therapeutic efficacy.

Palbociclib is metabolized primarily in the liver via CYP3A. Dose adjustments may be necessary for patients with moderate to severe hepatic impairment. In patients with renal impairment, especially severe cases, close monitoring is advised, although no major dose changes are typically required.

Strong CYP3A inhibitors (e.g., ketoconazole) can increase Palbociclib levels, raising the risk of toxicity, while strong inducers (e.g., rifampin) can reduce its efficacy. Co-administration should be avoided or closely monitored, and dose adjustments may be needed.

Resistance to Palbociclib may develop through various mechanisms, including loss of Rb protein function, amplification of CDK6, or activation of alternate cell cycle pathways. Understanding these mechanisms is essential for developing next-line therapies after disease progression.

Yes, but it is typically used in combination with ovarian suppression therapy (e.g., with a GnRH agonist) and an aromatase inhibitor or fulvestrant to ensure complete estrogen blockade in premenopausal patients.

Yes. The FDA has approved Palbociclib for use in male patients with HR+/HER2- advanced or metastatic breast cancer, often in combination with aromatase inhibitors and a GnRH analog to suppress testicular androgen production.